NEW YORK (GenomeWeb News) – Beckman Coulter said today that it has licensed certain rights to hepatitis C virus testing from Siemens Healthcare Diagnostics.
Beckman said that under the agreement it received rights to develop, manufacture, and sell a quantitative viral load HCV blood test for use on a molecular diagnostics instrument. The firm is developing a next-generation molecular diagnostics platform, called the UniCel DxN, which it plans to launch in 2010.
“Routine molecular testing is the fastest growing segment in clinical diagnostics and represents an important part of our growth strategy,” said Beckman Coulter Chairman, President and CEO Scott Garrett in a statement. “The addition of HCV will enhance our infectious disease test menu while furthering our dedication to improving patient health and reducing the cost of care.”
Beckman said that it would take a charge of $12 million in the second quarter as a result of the license.
Further terms of the agreement were not disclosed.